US-based biotechnology company Sanaria has reported positive results from a Phase II clinical trial of its PfSPZ Vaccine to fight malaria.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The trial was conducted by a team of clinical investigators at the Naval Medical Research Center and Walter Reed Army Institute of Research and was headed by Captain Judith Epstein and Major Kris Paolino.

It enrolled 69 volunteers aged between 19 and 45, out of whom 45 volunteers were administered three to five rapid 0.5mL injections by direct venous inoculation of the PfSPZ Vaccine.

The PfSPZ Vaccine is composed of live, purified, weakened malaria parasites that cannot cause malaria.

"The PfSPZ Vaccine is composed of live, purified, weakened malaria parasites that cannot cause malaria."

After being treated for three weeks, 89% volunteers received protection against Plasmodium falciparum malaria parasites, which were similar to those in the vaccine transmitted after being exposed to malaria-infected mosquitoes.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Four out of five or 80% of the volunteers were immune to parasites that were different from those in the vaccine and following 24 weeks after the last dosage, 63% of volunteers were protected against parasites similar to those in the vaccine.

Sanaria founder and CEO Stephen Hoffman said: “The findings from this research, particularly the protection achieved with just three doses of vaccine and the protection against parasites significantly different than those administered, lays a solid foundation for the ongoing clinical trial expected to finalise the immunisation regimen required for licensure of Sanaria PfSPZ Vaccine.”

Sanaria is planning to conduct future clinical trials of the PfSPZ Vaccine in Africa, the US, and Europe to obtain license of the product for its usage in mass vaccination programmes in the countries most affected by malaria.


Image: Photomicrograph displaying Plasmodium falciparum parasite. Photo: courtesy ofCenters for Disease Control and Prevention/Dr Mae Melvin/Transwiki approved by: w:en:User:Dmcdevit/Wikipedia.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact